| [1] |
Kaji M,Watanabe A,Aizawa H. Differences in clinicaI features between influenza A H1N1, A H3N2, and B in adult patients[J].Respirology, 2003, 8(2):231-233.
|
| [2] |
Goldstein E,Cobey S,Takahashi S, et al. Predicting the epidemic sizes of influenza A/H1N1, A/H3N2, and B: a statisticaI method[J]. PLoS Med, 2011, 8(7):e1001051.
|
| [3] |
Feng L,Shay DK,Jiang Y, et al.Influenza-associated mortality in temperate and subtropical Chinese cities，2003-2008[J]. Bull world Health Organ，2012，90(4):279-288.
|
| [4] |
Pleschka S. Overview of influenza viruses[J]. Curr Top Microbiol Immunol, 2013, 370:1-20.
|
| [5] |
Yu H,Alonso WJ,Feng L, et al. Characterization of regional influenza seasonality patterns in China and implications for vaccination strategies：spatio-temporal modeling of surveillance data[J]. PLoS Med, 2013, 10(11):e1001552.
|
| [6] |
Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016-2017.pdf[EB/OL].
URL
|
| [7] |
Ruttimann RW,Bonvehi PE,Vilar-Compte D, et al. Influenza among the elderly in the Americas: a consensus statement[J]. Rev Panam Salud Publica, 2013, 33(6):446-452.
|
| [8] |
Yu H,Huang J,Huai Y, et al. The substantial hospitalization burden of influenza in central China: surveillance for severe, acute respiratory infection, and influenza viruses，2010-2012[J].Influenza Other Respir Viruses, 2014，8(1):53-65.
|
| [9] |
Yang J,Jit M,Leung KS, et al.The economic burden of influenza-associated outpatient visits and hospitalizations in China:a retrospective survey[J]. Infect Dis Poverty, 2015, 4:44.
|
| [10] |
Fukumi H. History of influenza vaccine[J]. Uirusu, 1985, 35(2):107-122.
|
| [11] |
Tricco AC,Chit A,Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis[J]. BMC Med, 2013, 11:153.
|
| [12] |
Grohskopf LA,Sokolow LZ,Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2017-18 Influenza Season[J].MMWR Recomm Rep, 2017, 66(2):1-20.
|
| [13] |
冯录召，杨鹏，张涛，等.中国季节性流感疫苗应用技术指南（2014-2015）[J].中华流行病学杂志，2014，35（12）：1295-1319.
|
| [14] |
Cox RJ,Brokstad KA,Zuckerman MA, et al. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination[J]. Vaccine, 1994, 12(11):993-999.
|
| [15] |
Brokstad KA,Cox RJ,Olofsson J, et al. Parenteral influenza vaccination induces a rapid systemic and local immune response[J]. J Infect Dis, 1995, 171(1):198-203.
|
| [16] |
Jameson J,Cruz J,Ennis FA. Hutrlan eytotoxic T-lymphocyte repertoire to influenza A viruses[J]. J Virol, 1998, 72(11):8682-8689.
|
| [17] |
DiazGranados CA,Dunning AJ,Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults[J]. N Engl J Med, 2014, 371(7):635-645.
|
| [18] |
Cate TR,Couch RB,Parker D, et al. Reactogenicitv, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines-1978[J]. Rev Infect Dis, 1983, 5(4):737-747.
|
| [19] |
星一，刘民.流感灭活疫苗在中国应用效果的Meta分析[J].中华流行病学志，2009，30（4）：368-370.
|
| [20] |
刘民，刘改芬，王岩，等.北京市老年人群流行性感冒疫苗免疫效果及成本效益评价[J].中华流行病学杂志，2005，26（6）：412-416.
|
| [21] |
Nichol KL,Nordin JD,Nelson DB, et al. Effectiveness of influenza vaccine in the community-dwelling elderly[J]. N Engl J Med, 2007, 357(14):1373-1381.
|
| [22] |
Fireman B,Lee J,Lewis N, et al. Influenza vaccination and mortality: differentiating vaccine effects from bias[J]. Am J Epidemiol, 2009, 170(5):650-656.
|
| [23] |
Nichol KL,Nordin J,Mullooly J, et al. Influenza vaccination and reduction in hosPitalizations for cardiac disease and stroke among the elderly[J]. N Engl J Med, 2003, 348(14):1322-1332.
|
| [24] |
董振英，吴疆，褚天新，等.流行性感冒疫苗保护效果和成本效益分析[J].中华流行病学杂志，2003，24(1)：80.
|
| [25] |
Peasah SK,Azziz-Baumgartner E,Breese J, et al. Influenza cost and cost-effectiveness studies globally-areview[J]. Vaccine, 2013, 31(46):5339-5348.
|
| [26] |
Wang IK,Lin CL,Chang YC, et al. Effectiveness of influenza vaccination in elderly diabetic patients: a retrospective cohort study[J]. Vaceine, 2013, 31(4):718-724.
|
| [27] |
Margolis KL,Nicho1 KL,Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial[J]. JAMA, 1990, 264(9):1139-1141.
|
| [28] |
Govaert TM,Dinant GJ,Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial[J]. BMJ, 1993, 307(6910):988-990.
|
| [29] |
Nichol KL,Margolis KL,Lind A, et al. Side effects associated with infiuenza vaccination in healthy working adults. A randomized，placebo-controlled trial[J]. Arch Intern Med, 1996, 156(14):1546-1550.
|
| [30] |
Bridges CB,Thornpson WW,Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial[J]. JAMA, 2000, 284(13):1655-1663.
|
| [31] |
WHO. Vaccines against influenza WHO position paper-November 2012[J]. Wkly Epidemiol Rec, 2012, 87(47): 461-476.
|
| [32] |
Flore AE,Uyeki TM,Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices(ACIP), 2010[J]. MMWR Recomm Rep, 2010, 59(8):1-62.
|
| [33] |
Lasky T,Terracciano GJ,Magder L, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines[J].N Engl J Med, 1998, 339(25):1797-1802.
|
| [34] |
Juurlink DN,Stukel TA,Kwong J, et al. Guillain Barre syndrome after influenza vaccination in adults: a population-based study[J]. Arch Intern Med, 2006, 166(20):2217-2221.
|
| [35] |
Baxter R,Bakshi N,Fireman B, et al. Lack of association of Guillain-Barre syndrome with vaccinations[J].Clin Infect Dis, 2013, 57(2):197-204.
|
| [36] |
Vellozzi C,Burwen DR,Dobardzic A, et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring[J]. Vaccine, 2009, 27(15):2114-2120.
|
| [37] |
Yang J,Atkins KE,Feng L, et al. Seasonal influenza vaccination in China: Landscape of diverse regional reimbursement policy, and budget impact analysis[J]. Vaccine, 2016, 34(47):5724-5735.
|
| [38] |
Zhou L,Su Q,Xu Z, et al. Seasonal influenza vaccination coverage rate of target groups in selected cities and provinces in China by season(2009/10 to 2011/12)[J]. PLos One, 2013, 8(9):e73724.
|
| [39] |
Zhang Y,Muscatello DJ,Wang Q, et al. Overview of influenza vaccination policy in Beijing, China: current status and future prospects[J]. J Public Health Policy, 2017, 38(3):366-379.
|
| [40] |
Hospital Influenza Workgroup Singapore.Hospital Influenza Workgroup Management of Novel influenza epidemics in Singapore: Consensus Recommendations from the Hospital Influenza Workgroup(Singapore)[J]. Singapore Med J, 2009, 50(6):567-580.
|
| [41] |
Michel JP. Updated vaccine guidelines for aging and aged citizens of Europe[J]. Expert Rev Vaccines, 2010, 9(3 Suppl):7-10.
|
| [42] |
Choi WS,Choi JH,Kwon KT, et al. Revised adult immunization guideline recommended by the korean society of infectious diseases, 2014[J]. Infect Chemother, 2015, 47(2):154.
|
| [43] |
Australian and New Zealand Society for Geriatric Medicine Position Statement. Immunisation of older people[J]. Australas J Ageing, 2016, 35(1):67-73.
|
| [44] |
中华预防医学会.肺炎链球菌性疾病相关疫苗应用技术指南（2012版）[J].中华流行病学杂志，2012，33（11）：1101-1110.
|
| [45] |
WHO.23-valent pneumococcal polysaccharide vaccine. WHO position paper[J]. Wkly Epidemiol Rec, 2008, 83(42):373-384.
|
| [46] |
Kelley MA,Weber DJ,Gilligan P, et al.Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin[J]. Clin Infect Dis, 2000, 31(4):1008-1011.
|
| [47] |
Evers SM,Ament AJ,Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumocoecal disease in the elderly: an update for 10 Western European countries[J]. Eur J Clin Microbiol Infect Dis, 2007, 26(8):531-540.
|
| [48] |
王辉，俞云松，刘勇，等.2002-2003年中国社区呼吸道感染常见病原菌的耐药性监测[J].中华结核和呼吸杂志，2004，27（3）：155-160.
|
| [49] |
刘慧，张天托，吴本权，等.老年社区获得性肺炎住院患者的临床资料分析[J].中华内科杂志，2007，46（10）：810-814.
|
| [50] |
孙宏莉，徐英春，王辉，等.2004-2005年中国社区获得呼吸道感染常见病原菌耐药性研究[J].中国感染与化疗杂志，2008，8（1）：24-29.
|
| [51] |
刘又宁，陈民钧，赵铁梅，等.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志，2006，29（1）：3-8.
|
| [52] |
李耘，吕媛，薛峰，等.卫生部全国细菌耐药监测网(Mohnarin)2011-2012年革兰阳性菌耐药监测报告[J].中国临床药理学杂志，2014，21（3）：5133-5137.
|
| [53] |
何丽娟，徐国纲，李泽年.肺炎链球菌的研究现状和耐药机制与应对措施[J].老年医学与保健，2016，22（6）：419-421.
|
| [54] |
Makela PHBJC. History of pneumococcal immunization[M]. Washington, DC: ASM Press, 2008:19-29.
|
| [55] |
Robbins JB,Austrian R,Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polvsaccharide vaccine with emphasis on the cross reactive types within groups[J]. J Infect Dis, 1983, 148(6):1136-1159.
|
| [56] |
Song JY,Moseley MA,Burton RL, et al. Pneumococcal vaccine and opsonic pneumococcal antibody[J]. J Infect Chemother, 2013, 19(3):412-425.
|
| [57] |
Pilishvili T,Lexau C,Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine[J]. J Infect Dis, 2010, 201(1):32-41.
|
| [58] |
Centers for Disease Control and Prevention(CDC). Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine-United States, 2007[J]. MMWR Morb MortaI Wkly Rep, 2010, 59(9):253-257.
|
| [59] |
Food and Drug Administration. FDA expands use of Prevnar 13 vaccine for people ages 50 and older. Silver Spring, MD: US Department of Health and Human Services. Food and Drug Administration: 2011[EB/OL]. Accessed October 10, 2012.
URL
|
| [60] |
Pilishvili T,Bennett NM. Pneumococcal disease prevention among adults：strategies for the use of pneumococcal vaccines[J]. Am J Prey Med, 2015, 49(6 Suppl 4):383-390.
|
| [61] |
Simonsen V,Brandao AP,Brandileone MC, et al. Immunogenicity of a 23-valent pneumococcal polysaceharide vaccine in Brazilian elderly[J]. Braz J Med Biol Res, 2005, 38(2):251-260.
|
| [62] |
Lee H,Nahm MH,Kim KH. The effect of age on the response to the pneumococcal polysaccharide vaccine[J]. BMC Infect Dis, 2010, 10:60.
|
| [63] |
ACIP. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices(ACIP)[J]. MMWR Recomm Rep, 1997, 46(8):1-24.
|
| [64] |
Shiramoto M,Hanada R,Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults[J]. Hum Vaccin Immunother, 2015, 11(9):2198-2206.
|
| [65] |
Jackson LA,Gurtman A,Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conj ugate vaccine in adults 70 years of age and older previously vaccinated with 23 valent pneumococcal polysaccharide vaccine[J]. Vaccine, 2013, 31(35):3585-3593.
|
| [66] |
徐英，董碧蓉.23价肺炎球菌多糖疫苗预防老年人下呼吸道感染的效果考察[J].中国计划免疫，2005，11（4）：287-291.
|
| [67] |
Ochoa-Gondar O,Vila-Corcoles A,Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged >/=60 years: 3 years of follow-up in the CAPAMIS study[J]. Clin Infect Dis, 2014, 58(7):909-917.
|
| [68] |
Maruyama T,Taguchi O,Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents：double blind，randomised and placebo controlled trial[J].BMJ, 2010, 340:c1004.
|
| [69] |
Moberley S,Holden J,Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults[J]. Cochrane Database Syst Rev, 2013, 1:Cd000422.
|
| [70] |
Zhao D,Gai Tobe R,Cui M, et al. Cost-effectiveness of a 23-valent pneumococcal polvsaccharide vaccine immunization programme for the elderly in Shanghai, China[J]. Vaccine, 2016, 34(50):6158-6165.
|
| [71] |
Zhang YY,Tang XF,Du CH, et al. Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: a meta-analysis[J]. Hum Vaccin Immunother, 2016, 12(12):3056-3064.
|
| [72] |
Chang YC,Chou YJ,Liu JY, et al. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan-a representative population-based comparative study[J]. J Infect, 2012, 65(3):231-238.
|
| [73] |
Nichol KL. The additive benefits of influenza and pneumococeal vaccinations during influenza seasons among elderly persons with chronic lung disease[J]. Vaccine, 1999, 17(Suppl 1):S91-93.
|
| [74] |
Grilli G,Fuiano L,Biasio LR, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals[J]. Eur J Epidemiol, 1997, 13(3):287-291.
|
| [75] |
de Soarez PC,Sartori AM,Freitas AC, et al. Cost effectiveness analysis of universal vaccination of adults aged 60 years with 23-valent pneumococcal polysaccharide vaccine versus current practice in Brazil[J]. PLoS One, 2015, 10(6):e0130217.
|
| [76] |
Jackson LA,Benson P,Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine[J].JAMA, 1999, 281(3):243-248.
|
| [77] |
张国辉，郑东旖，时念民，等.北京市朝阳区部分社区老年人的肺炎疫苗接种率及影响因素分析[J].中国生物制品学杂志，2013，26（1）：93-95.
|
| [78] |
尤志军，林冰，高中.上海市青浦区老年人肺炎疫苗接种率及其影响因素分析[J].医药与保健，2015，23（3）：89.
|
| [79] |
朱宝，黄蓉娜，杨汝沛，等.成都市户籍老年人肺炎疫苗接种率及影响因素调查[J].预防医学情报杂志，2017，33（1）：75-80.
|
| [80] |
Kobayashi M,Bennett NM,Gierke R, et al. Intervalsbetween PCVl3 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices(ACIP)[J]. MMWR Morb Mortal Wkly Rep, 2015，64(34):944-947.
|
| [81] |
Berical AC,Harris D,Dela Cruz CS. Pneumococcal vaccination strategies. An update and perspective[J]. Ann Am Thorac Soc, 2016, 13(6):933-944.
|
| [82] |
Centers for Disease Control and Prevention(CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasivepneumoeoecal disease among adults using the 23-valent pneumococcal polysaccharide vaccine(PPSV23)[J]. Morb Mortal Wkly Rep, 2010, 59(34):1102-1106.
|
| [83] |
Advisory Committee on Immunization Practices.Recommended adult immunization schedule: United States, 2011[J].Ann Intern Med, 2011, 154(3):168-173.
|